Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novamind Inc (OP: NVMDF ) N/A UNCHANGED Last Price Updated: 3:36 PM EDT, Jun 13, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Novamind Inc < Previous 1 2 3 Next > Novamind Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site September 30, 2021 TORONTO, ON / ACCESSWIRE / September 30, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... From Novamind Inc. Via AccessWire Novamind Announces DTC Eligibility for its Common Shares September 24, 2021 TORONTO, ON / ACCESSWIRE / September 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... From Novamind Inc. Via AccessWire Novamind to Present at Benzinga Healthcare Conference September 23, 2021 Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare TORONTO, ON / ACCESSWIRE / September 23, 2021 / Novamind Inc.... From Novamind Inc. Via AccessWire Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF September 20, 2021 TORONTO, ON / ACCESSWIRE / September 20, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... From Novamind Inc. Via AccessWire Novamind to Present at Life Sciences Investor Forum September 14, 2021 TORONTO, ON / ACCESSWIRE / September 14, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... From Novamind Inc. Via AccessWire Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial September 13, 2021 Cedar Clinical Research to Host Phase III Trial for Investigational Therapy for Schizophrenia TORONTO, ON / ACCESSWIRE / September 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or... From Novamind Inc. Via AccessWire Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? September 09, 2021 By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... Via Benzinga Novamind Uplists to OTCQB Venture Market September 09, 2021 TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... From Novamind Ventures Inc. Via AccessWire Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 08, 2021 TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... From Novamind Inc. Via AccessWire Psychedelic Drug Industry Report Card For 2021 September 01, 2021 In assessing the psychedelic drug industry, a primary focus for investors is drug development. Via Talk Markets Novamind Divests Non-Core Retreat Investment August 11, 2021 TORONTO, ON / ACCESSWIRE / August 11, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today... From Novamind Inc. Via AccessWire Which Psychedelic Drug Has The Most Commercial Potential? August 10, 2021 As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. Via Talk Markets Novamind Strengthens Mental Health Expertise, Adds Communications Leader August 06, 2021 Samantha DeLenardo joins from CAMH, Canada's largest mental health teaching hospital and leader in mental health research TORONTO, ON / ACCESSWIRE / August 6, 2021 / Novamind Inc., (CSE:NM)(OTC... From Novamind Inc. Via AccessWire Exposures COVID-19 Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected August 02, 2021 Last week in Psychedelics: Via Benzinga Novamind Opens 5th Clinic Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions July 29, 2021 Company executes organic growth mandate, on track to open four new clinics by Q3 2021 TORONTO, ON / ACCESSWIRE / July 29, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the... From Novamind Inc. Via AccessWire Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States July 21, 2021 Aims to increase visibility and facilitate investment for United States investors TORONTO, ON / ACCESSWIRE / July 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the... From Novamind Inc. Via AccessWire Novamind Selected as Research Site for Bionomics' PTSD Clinical Trial July 08, 2021 Cedar Clinical Research to Host Phase IIb Trial for a Novel PTSD Treatment TORONTO, ON / ACCESSWIRE / July 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a... From Novamind Inc. Via AccessWire Novamind Launches Psychedelic Therapy Frontiers Podcast June 30, 2021 Aimed at an audience of psychedelic medicine researchers and clinicians TORONTO, ON / ACCESSWIRE / June 30, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a... From Novamind Inc. Via AccessWire Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer June 23, 2021 - Led first-of-its-kind study of group psilocybin therapy for cancer patients with depression - Co-Investigator on a study to evaluate ketamine as a treatment for opioid use disorder - Will lead... From Novamind Inc. Via AccessWire Topics Death Exposures Death Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company June 17, 2021 TORONTO, ON / ACCESSWIRE / June 17, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces... From Novamind Inc. Via AccessWire Novamind to Present at the H.C. Wainwright Psychedelics Conference on June 17, 2021 June 15, 2021 Novamind to be featured in panel discussions on the disruptive potential of psychedelic treatments TORONTO, ON / ACCESSWIRE / June 15, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind"... From Novamind Inc. Via AccessWire Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers June 14, 2021 Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi... Via Benzinga Topics Initial Public Offering Exposures Securities Market Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers June 10, 2021 Novamind and the Wholeness Center to launch clinical offering in Utah and Colorado TORONTO, ON / ACCESSWIRE / June 10, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the... From Novamind Inc. Via AccessWire Exposures COVID-19 Novamind Reports Fiscal Q3 Financial Results and Operating Highlights June 01, 2021 - Revenue of $1,846,132 for Fiscal Q3 2021, +43% quarter-over-quarter - Announced doubling of clinic network by September 2021 - Forecasting 65,000 clinic visits in 2021, +225% year-over-year TORONTO,... From Novamind Inc. Via AccessWire Video: Experts Discuss Use Of Psychedelics In Mental Health Settings May 11, 2021 The psychedelics industry has started to gain serious traction and is attracting lots of attention these days. However, what many people may not kn... Via Benzinga Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M May 10, 2021 Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound... Via Benzinga Novamind And Field Trip Expand Footprint Of Psychedelic Clinics May 05, 2021 Novamind Inc. (OTC:NVMDF), a company specializing in mental ... Via Benzinga Novamind Announces Participation at the Planet MicroCap Showcase on April 20 - 22, 2021 April 20, 2021 TORONTO, ON / ACCESSWIRE / April 20, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will... From Novamind Inc. Via AccessWire Novamind to Present at the Planet MicroCap Virtual Event on April 22, 2021 April 19, 2021 TORONTO, ON / ACCESSWIRE / April 19, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will... From Novamind Inc. Via AccessWire Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021 April 19, 2021 LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be... From Stock News Now Via AccessWire Topics Cannabis Exposures Cannabis < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.